U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of...
with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
AstraZeneca’s drug, to be sold under the brand name Beyfortus, is a laboratory-made version of an antibody that helps the immune system fight off RSV. Under the FDA approval, babies — including preterm infants — can receive a single injection to protect against their first season of RSV, which typically lasts about five months. Children up to age 2 can receive another dose to protect them during their second season facing the virus. and the U.K. Sanofi did not immediately announce the U.S.
FDA officials approved the drug based on three studies showing Beyfortus reduced the risk of RSV infection between 70% and 75% among infants and children 2 and younger. Advisers to the Centers for Disease Control and Prevention will meet early next month to recommend exactly who should get the drug.A similar antibody drug won FDA approval more than 20 years ago, but it’s only recommended for high-risk babies and requires monthly injections. Pediatricians say the drug is underutilized and they expect the longer-lasting effect of AstraZeneca’s shot to improve uptake.In the U.S.
After decades of setbacks for RSV research, drugmakers have made big strides this year, launching the first vaccines against the virus. In May, the FDA approved two RSV vaccines for
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
FDA approves new drug to protect babies from RSVThe FDA approved a new drug to protect babies from RSV, the leading cause of hospitalization for U.S. infants.
Les mer »
New drug to protect babies and toddlers from RSV gets FDA approval ahead of cold seasonLast year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
Les mer »
New drug to protect babies and toddlers from RSV gets FDA approval ahead of cold seasonLast year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
Les mer »
New drug to protect babies and toddlers from RSV gets FDA approval ahead of cold seasonU.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year.
Les mer »
FDA approves antibody to protect infants from RSV | CNNParents and pediatricians will have a new option this fall to protect babies from a lung-attacking virus that is the leading cause of hospitalization in infants under a year of age in the United States every year.
Les mer »
FDA approves antibody shot to protect infants from potentially deadly virus RSVThis injection was approved to protect against the annual leading cause of hospitalization in infants under a year old in the U.S.
Les mer »